Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.3.9824.5254
Address
Level 3 62 Lygon Street Carlton, Victoria (VIC) 3053
Description
Chimeric Therapeutics Ltd. is a clinical stage cell therapy company, which engages in the development and commercialization of cell therapies in oncology. Its products include NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company was founded by Paul A. Hopper in 2020 and is headquartered in Carlton South, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.02
Trade Value (12mth)
AU$6,662.00
1 week
0%
1 month
-20%
YTD
-40%
1 year
-76.67%
All time high
0.40
EPS 3 yr Growth
-77.50%
EBITDA Margin
N/A
Operating Cashflow
-$8m
Free Cash Flow Return
-185.70%
ROIC
-308.20%
Interest Coverage
N/A
Quick Ratio
0.30
Shares on Issue (Fully Dilluted)
1055m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
17 June 25 |
Translational data shows persistence of CHM CDH17
×
Translational data shows persistence of CHM CDH17 |
10 June 25 |
Chimeric receives $2.5 M advance on FY25 R&D tax incentive
×
Chimeric receives $2.5 M advance on FY25 R&D tax incentive |
04 June 25 |
CHM CDH17 receives FDA Fast Track
×
CHM CDH17 receives FDA Fast Track |
29 May 25 |
Application for quotation of securities - CHM
×
Application for quotation of securities - CHM |
28 May 25 |
Change in substantial holding - PH
×
Change in substantial holding - PH |
26 May 25 |
Prospectus
×
Prospectus |
26 May 25 |
Letter to Shareholders
×
Letter to Shareholders |
26 May 25 |
Application for quotation of securities - CHM
×
Application for quotation of securities - CHM |
22 May 25 |
Presentation to investor webinar
×
Presentation to investor webinar |
21 May 25 |
CHM CDH17 ADVANCES TO DOSE LEVEL 2
×
CHM CDH17 ADVANCES TO DOSE LEVEL 2 |
20 May 25 |
$6.6 million Placement to advance clinical trial pipeline
×
$6.6 million Placement to advance clinical trial pipeline |
20 May 25 |
Proposed issue of securities - CHM
×
Proposed issue of securities - CHM |
20 May 25 |
Proposed issue of securities - CHM
×
Proposed issue of securities - CHM |
20 May 25 |
Investor webinar
×
Investor webinar |
16 May 25 |
Trading Halt
×
Trading Halt |
15 May 25 |
Pause in Trading
×
Pause in Trading |
15 May 25 |
Trading Halt
×
Trading Halt |
15 May 25 |
ADVENT-AML Phase 1B clinical trial update
×
ADVENT-AML Phase 1B clinical trial update |
09 May 25 |
Application for quotation of securities - CHM
×
Application for quotation of securities - CHM |
01 May 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
01 May 25 |
Change of Director's Interest Notice PH
×
Change of Director's Interest Notice PH |
01 May 25 |
Change in substantial holding
×
Change in substantial holding |
30 April 25 |
Application for quotation of securities - CHM
×
Application for quotation of securities - CHM |
30 April 25 |
Application for quotation of securities - CHM
×
Application for quotation of securities - CHM |
24 April 25 |
Completion of Entitlement Offer
×
Completion of Entitlement Offer |
24 April 25 |
EMORY JOINS CHM CDH17 PHASE 1/2 CLINICAL TRIAL
×
EMORY JOINS CHM CDH17 PHASE 1/2 CLINICAL TRIAL |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.